The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Erasca announced a $500 million public offering of common stock on July 13, which later closed on July 15 as an upsized offering of 36,142,857 shares at $17.50 per share. Gross proceeds reached approximately $632.5 million following the full exercise of the underwriters' option to purchase additional shares. However, on July 20, The Schall Law Firm announced a class action lawsuit opportunity against Erasca for allegedly misleading the market regarding preclinical data.